NEW YORK, September 26 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. , a biotechnology company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of infectious diseases, particularly the treatment of hepatitis C, has posted to shareholders a notice convening its AGM. The AGM will take place at the Conference Room at the Company’s Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 4:00 p.m., on October 25, 2006.
At the AGM it is proposed that:
- the annual reports for the year ended 31 December 2005 be received;
- Kesselman & Kesselman (PricewaterhouseCoopers) be reappointed as the Company’s auditors; and
- Messrs Michael Weiss, Ben Zion Weiner and William Kennedy be re-appointed as Directors of the Company.
Contacts: XTL Ron Bentsur, Chief Executive Officer Tel: +1-(212)-531-5960 ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL is engaged in the acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTL’s hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecules. XTL is publicly traded on the Nasdaq, London, and Tel-Aviv Stock Exchanges .
XTL Biopharmaceuticals Ltd
CONTACT: Contacts: XTL, Ron Bentsur, Chief Executive Officer Tel:+1-(212)-531-5960
